1985-P: Increasing Adoption of Diabetes Technology among Children and Youth with Type 1 Diabetes: T1D Exchange Quality Improvement Collaborative

Introduction and Objective: Continuous Glucose Monitoring (CGM) and Automated Insulin Delivery (AID) systems improve type 1 diabetes management. CGM is recommended as standard of care for pediatric type 1 diabetes management. AID systems improve blood glucose levels and quality of life for children. The T1D Exchange Quality Improvement Collaborative supports participating centers in implementing system-level interventions to increase access to diabetes technology Methods: Monthly data from 1/2023 to 9/2025 were aggregated from 25 pediatric centers that applied quality improvement (QI) principles, including the Ishikawa diagram, process map, effort/impact matrix tool, and Plan - Do - Study - Act cycles to test and expand QI interventions. Statistical process control charts were used to assess trends in CGM and AID use Results: CGM use increased from 83% to 91%, representing a sustained improvement with an upward shift in the centerline. AID use increased from 58% to 64%. Both measures demonstrated upward shifts over time, with multiple centers achieving performance above their pre-intervention baselines Conclusion: Implementation of QI intervention across clinics was associated with sustained increases in CGM use and AID adoption. These improvements demonstrate that system-level interventions targeting workflow redesign, patient engagement, and reducing barriers can successfully increase diabetes technology utilization in clinical settings Disclosure O. Odugbesan: None. T.R. Bol: None. T. Wright: None. N. Fogel: Other - Spouse's employer; Current; Medline. M. Gallagher: Research Support; Current; BioMarin Pharmaceutical Inc., T1D Exchange, IQVIA Inc., MannKind Corporation, National Institute of Diabetes and Digestive and Kidney Diseases, Sanofi-Aventis U.S., Diamyd. P.C. Hanley: None. R.E. Izquierdo: None. E.A. Mann: None. A. Roberts: None. J. Sanchez: Advisory Panel; Ended; Sanofi. A. Guarneri: None. K. Cossen: None. C. Demeterco-Berggren: Advisory Panel; Ended; Sanofi. Board Member; Current; Glooko, Inc. Research Support; Ended; Medtronic. R. Wolf: Research Support; Current; Lilly Diabetes. Research Support; Ended; Novo Nordisk. Research Support; Current; Sanofi. Consultant; Current; Sanofi. J.C. Wong: Research Support; Ended; Abbott Diabetes. G.T. Alonso: None. M.K. Kamboj: None. N. Rioles: None.